Expert Opinion on Investigational Drugs, Volume 33, Issue 1 (2024)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 33, Issue 1 (2024)

See all volumes and issues
Volume 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections
Katherine Y. Le & Michael Otto
Pages: 1-3
Published online: 12 Feb 2024
First Page PreviewforApproaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections | Full Text | References | PDF (177.8 KB) | EPUB
  • 690 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Potential of muvalaplin as a lipoprotein(a) inhibitor
Amanda J. Hooper, P. Mihika S. Fernando & John R. Burnett
Pages: 5-7
Published online: 12 Feb 2024
First Page PreviewforPotential of muvalaplin as a lipoprotein(a) inhibitor | Full Text | References | PDF (167.1 KB) | EPUB
  • 1711 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Drug Evaluation

Review Article
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase
Xiao-Jian Zhou, Steven S Good, Keith Pietropaolo, Qi Huang, Adel Moussa, Janet MJ Hammond & Jean-Pierre Sommadossi
Pages: 9-17
Published online: 12 Feb 2024
AbstractforBemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase | Full Text | References | PDF (1.1 MB) | EPUB
  • 954 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access
Review Article
Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms
Jenifer Sassarini & Richard A Anderson
Pages: 19-26
Published online: 12 Feb 2024
AbstractforElinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms | Full Text | References | PDF (3.5 MB) | EPUB
  • 2381 Views
  • 0 CrossRef citations
  • 0Altmetric
Open Access

Review

Review Article
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options
Eren Arslan Davulcu, Merve Beyza Oğuz, Emre Kılıç & Ahmet Emre Eşkazan
Pages: 27-37
Published online: 12 Feb 2024
AbstractforTreatment of anemia in myelofibrosis: focusing on novel therapeutic options | Full Text | References | PDF (367.7 KB) | EPUB
  • 340 Views
  • 0 CrossRef citations
  • 0Altmetric
Review Article
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review
Paola Rogliani, Gian Marco Manzetti, Federica Roberta Bettin, Maria D’Auria & Luigino Calzetta
Pages: 39-49
Published online: 12 Feb 2024
AbstractforInvestigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review | Full Text | References | PDF (3 MB) | EPUB
  • 426 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration
Yimin Yu, Jingjing He, Zhiwei Huang, Yan Li, Ying Wu, Yifeng Shen, Yanling Zhou, Cungang Bao, Zhiping Jin & Huafang Li
Pages: 51-61
Published online: 12 Feb 2024
AbstractforSafety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration | Full Text | References | PDF (1.3 MB) | EPUB | Supplemental
  • 113 Views
  • 0 CrossRef citations
  • 0Altmetric
Article
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study
Yicong Bian, Sheng Ma, Qingqing Yao, Tao Hu, Mingjing Ge, Hongting Li, Shansong Zheng, Zheming Gu, Hao Feng, Zhenwen Yu, Chenrong Huang, Hua Zhang, Limei Zhao & Liyan Miao
Pages: 63-72
Published online: 12 Feb 2024
AbstractforPharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study | Full Text | References | PDF (2.2 MB) | EPUB | Supplemental
  • 139 Views
  • 0 CrossRef citations
  • 0Altmetric

Explore articles